Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 6 Correlation between CDKN1B expression in tumor tissues and clinical parameters of PCa patients

From: Extrachromosomal circular DNA promotes prostate cancer progression through the FAM84B/CDKN1B/MYC/WWP1 axis

Clinical characteristics

n = 38

CDKN1B IHC score

p-value

High (n = 20)

Low (n = 18)

Age (years)

≥ 66

17

8

9

0.5359

< 66

21

12

9

PSA (ng/mL)

≥ 9.67

13

7

6

0.9139

< 9.67

25

13

12

Gleason score

≤ 6

11

11

0

0.0007*

3 + 4

10

7

3

4 + 3

9

2

7

≥ 8

8

0

8

AR status

Positive

30

16

14

0.8668

Negative

8

4

4

p53 status

Positive

15

7

8

0.552

Negative

23

13

10

T stage

pT2

23

17

6

0.0042*

pT3

13

3

10

pT4

2

0

2

Lymph node metastasis

Absent

27

17

10

0.0457*

Present

11

3

8

  1. Chi-square test was used to analyze the correlation between gene expression in PCa tumor tissues and clinical characteristics of patients. PCa: prostate cancer; PSA: prostate-specific antigen; AR: androgen receptor; IHC: immunohistochemistry; *p < 0.05
Back to article page

Cellular & Molecular Biology Letters

ISSN: 1689-1392

Contact us